CAMP4 THERAPEUTICS CORP (CAMP) Fundamental Analysis & Valuation

NASDAQ:CAMP • US13463J1016

Current stock price

5 USD
-0.16 (-3.1%)
At close:
5.002 USD
+0 (+0.04%)
After Hours:

This CAMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CAMP Profitability Analysis

1.1 Basic Checks

  • In the past year CAMP has reported negative net income.
  • In the past year CAMP has reported a negative cash flow from operations.
  • CAMP had negative earnings in each of the past 5 years.
  • CAMP had negative operating cash flow in 4 of the past 5 years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • The Return On Assets of CAMP (-67.80%) is worse than 62.76% of its industry peers.
  • Looking at the Return On Equity, with a value of -166.67%, CAMP is doing worse than 66.60% of the companies in the same industry.
Industry RankSector Rank
ROA -67.8%
ROE -166.67%
ROIC N/A
ROA(3y)-74.52%
ROA(5y)-55.93%
ROE(3y)-126.05%
ROE(5y)-97.92%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CAMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10K -10K 20K 30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CAMP Health Analysis

2.1 Basic Checks

  • CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CAMP has been increased compared to 1 year ago.
  • Compared to 5 years ago, CAMP has more shares outstanding
  • There is no outstanding debt for CAMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • CAMP has an Altman-Z score of -1.68. This is a bad value and indicates that CAMP is not financially healthy and even has some risk of bankruptcy.
  • CAMP has a Altman-Z score (-1.68) which is in line with its industry peers.
  • There is no outstanding debt for CAMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.68
ROIC/WACCN/A
WACC9.03%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • CAMP has a Current Ratio of 7.13. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
  • CAMP's Current ratio of 7.13 is fine compared to the rest of the industry. CAMP outperforms 68.52% of its industry peers.
  • CAMP has a Quick Ratio of 7.13. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
  • CAMP has a better Quick ratio (7.13) than 68.91% of its industry peers.
Industry RankSector Rank
Current Ratio 7.13
Quick Ratio 7.13
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CAMP Growth Analysis

3.1 Past

  • CAMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.19%, which is quite impressive.
  • Looking at the last year, CAMP shows a very negative growth in Revenue. The Revenue has decreased by -95.11% in the last year.
  • Measured over the past years, CAMP shows a very negative growth in Revenue. The Revenue has been decreasing by -59.51% on average per year.
EPS 1Y (TTM)90.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.61%
Revenue 1Y (TTM)-95.11%
Revenue growth 3YN/A
Revenue growth 5Y-59.51%
Sales Q2Q%-46.63%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.78% on average over the next years. This is quite good.
  • CAMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 86.07% yearly.
EPS Next Y64.46%
EPS Next 2Y29.38%
EPS Next 3Y19.13%
EPS Next 5Y12.78%
Revenue Next Year-10.2%
Revenue Next 2Y13.33%
Revenue Next 3Y72.16%
Revenue Next 5Y86.07%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. CAMP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAMP. In the last year negative earnings were reported.
  • Also next year CAMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • CAMP's earnings are expected to grow with 19.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.38%
EPS Next 3Y19.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CAMP Dividend Analysis

5.1 Amount

  • No dividends for CAMP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAMP Fundamentals: All Metrics, Ratios and Statistics

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (3/20/2026, 8:00:03 PM)

After market: 5.002 +0 (+0.04%)

5

-0.16 (-3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-11
Inst Owners79.59%
Inst Owner Change60.43%
Ins Owners1.32%
Ins Owner Change0%
Market Cap259.60M
Revenue(TTM)3.50M
Net Income(TTM)-80.00M
Analysts85
Price Target8.93 (78.6%)
Short Float %1.2%
Short Ratio2.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-95.34%
Min EPS beat(2)-177.96%
Max EPS beat(2)-12.73%
EPS beat(4)2
Avg EPS beat(4)-41.99%
Min EPS beat(4)-177.96%
Max EPS beat(4)13.17%
EPS beat(8)2
Avg EPS beat(8)-340.59%
EPS beat(12)4
Avg EPS beat(12)-228.37%
EPS beat(16)7
Avg EPS beat(16)-175.52%
Revenue beat(2)1
Avg Revenue beat(2)11.76%
Min Revenue beat(2)-26.36%
Max Revenue beat(2)49.89%
Revenue beat(4)3
Avg Revenue beat(4)858.21%
Min Revenue beat(4)-26.36%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)456.44%
Revenue beat(12)6
Avg Revenue beat(12)303.88%
Revenue beat(16)6
Avg Revenue beat(16)226.5%
PT rev (1m)0%
PT rev (3m)2.94%
EPS NQ rev (1m)20.25%
EPS NQ rev (3m)28.41%
EPS NY rev (1m)0%
EPS NY rev (3m)7.67%
Revenue NQ rev (1m)195.83%
Revenue NQ rev (3m)343.75%
Revenue NY rev (1m)30%
Revenue NY rev (3m)424.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 74.17
P/FCF N/A
P/OCF N/A
P/B 5.41
P/tB 5.41
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.07
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.8%
ROE -166.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.52%
ROA(5y)-55.93%
ROE(3y)-126.05%
ROE(5y)-97.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.07%
Cap/Sales 8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.13
Quick Ratio 7.13
Altman-Z -1.68
F-Score4
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)27.81%
Cap/Depr(5y)118.7%
Cap/Sales(3y)89.92%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.61%
EPS Next Y64.46%
EPS Next 2Y29.38%
EPS Next 3Y19.13%
EPS Next 5Y12.78%
Revenue 1Y (TTM)-95.11%
Revenue growth 3YN/A
Revenue growth 5Y-59.51%
Sales Q2Q%-46.63%
Revenue Next Year-10.2%
Revenue Next 2Y13.33%
Revenue Next 3Y72.16%
Revenue Next 5Y86.07%
EBIT growth 1Y6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.78%
OCF growth 3YN/A
OCF growth 5YN/A

CAMP4 THERAPEUTICS CORP / CAMP Fundamental Analysis FAQ

What is the fundamental rating for CAMP stock?

ChartMill assigns a fundamental rating of 2 / 10 to CAMP.


What is the valuation status of CAMP4 THERAPEUTICS CORP (CAMP) stock?

ChartMill assigns a valuation rating of 0 / 10 to CAMP4 THERAPEUTICS CORP (CAMP). This can be considered as Overvalued.


Can you provide the profitability details for CAMP4 THERAPEUTICS CORP?

CAMP4 THERAPEUTICS CORP (CAMP) has a profitability rating of 1 / 10.


What is the financial health of CAMP4 THERAPEUTICS CORP (CAMP) stock?

The financial health rating of CAMP4 THERAPEUTICS CORP (CAMP) is 4 / 10.